Alecensa 150 mg hard capsules
Each hard capsule contains alectinib hydrochloride equivalent to 150 mg alectinib.
Excipients with known effect
Each hard capsule contains 33.7 mg lactose (as monohydrate) and 6 mg sodium (as sodium laurilsulfate).
For the full list of excipients, see section 6.1.
Hard capsule.
White hard capsule of 19.2 mm length, with “ALE” printed in black ink on the cap and “150 mg” printed in black ink on the body.
Alecensa as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
Treatment with Alecensa should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.
A validated ALK assay is necessary for the selection of ALK-positive NSCLC patients. ALK-positive NSCLC status should
